Glenmark’s European strategy takes a big leap with Tavulus launch in Spain

INDIA – Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company, today announced the launch of Tavulus, a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) in Spain for the treatment of chronic obstructive pulmonary disease (COPD).

COPD is a long-term condition that causes lung inflammation, lung tissue damage, and airway narrowing, all of which make breathing difficult.

Studies show that nearly 2.5 million people in Spain suffer from COPD. Glenmark will sell the powder under the brand name Tavulus.

Tavulus is expected to help a large number of patients in the country. It is a long-acting bronchodilator that helps to open the airways and allows more air to enter and exit the lungs. It also works to prevent COPD symptoms from worsening suddenly.

Commenting on the launch, Vice President – Business Development of Glenmark Pharmaceuticals Limited, Dr. Jiří Havránek, says, “The goal of COPD treatment has always been to provide quick symptomatic relief to patients, and reduce the risk of exacerbations. Since its launch, we have seen the multiple therapeutic benefits of Tavulus in other markets, and we are pleased to extend these benefits to patients in Spain.”

He added that the inhalation therapy has been shown to significantly aid in the daily management of COPD and that he remains hopeful that the drug will improve both COPD symptoms and quality of life in those who are most affected.

A Glenmark European subsidiary entered into a strategic, exclusive in-licensing agreement in November 2017 for the marketing of generic Tiotropium Bromide DPI in Western Europe and the United Kingdom.

Glenmark intends to launch the product in these markets under the brand names Tiogiva in the United Kingdom, Ireland, Sweden, Finland, and Norway; Tavulus in Denmark and the Netherlands; and Tiotropium Glenmark in Germany.

This milestone comes hot on the heels of another momentous approval of Glenmark’s fixed- dose combination nasal spray, Ryaltris, just a fortnight ago by the EU.

Receiving EU’s seal of approval means that Glenmark can engage in commercial sales in 13 countries across the EU and the UK, bolstering the company’s revenue from its respiratory therapy line.

Would you like to get regular updates of such news articles? Subscribe to our HealthCare Africa News, email newsletters, which provide the latest news insights from Africa and the World’s health, pharma and biotech industry. SUBSCRIBE HERE

Related posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.